Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
-
BUSINESS Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
-
BUSINESS Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
-
BUSINESS Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
-
BUSINESS AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
-
BUSINESS DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
-
ORGANIZATION Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
-
REGULATORY MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
-
REGULATORY MHLW’s Generic Roadmap Compilation in Homestretch
March 29, 2013
-
BUSINESS Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
-
BUSINESS ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
-
BUSINESS New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
-
BUSINESS Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
-
ORGANIZATION JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
-
REGULATORY CSIMC Expert Member Yoshiaki Kamoya (Executive Officer, Shionogi) Says Price Cuts for Long-Listed Drugs and Perpetuation of Premium for New Drug Development Should Be Discussed Together
March 22, 2013
-
ORGANIZATION JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
-
BUSINESS Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
-
BUSINESS Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
-
ORGANIZATION Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
-
BUSINESS Eli Lilly Japan Files Tadalafil for BPH, 3rd NDA for Same API
March 15, 2013
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…